Plain-English translation of NCT02830724 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach to cancer treatment using your own immune cells. Doctors will take white blood cells from your blood, train them in the lab to recognize and attack cancer cells that have a specific protein called CD70, and then give the trained cells back to you along with medication to help them work. The goal is to see if this approach is safe and whether it can shrink tumors in people with pancreatic cancer, kidney cancer, breast cancer, melanoma, or ovarian cancer.
Standard cancer treatments don't always work for advanced cancers that have spread or cannot be surgically removed. This trial exists to test whether using your own immune system—trained to recognize a specific target on cancer cells—might be a more effective way to fight these cancers.
You likely qualify if…
You likely don't qualify if…
First, doctors will collect white blood cells from your blood through a process called leukapheresis (similar to donating plasma). These cells will then be sent to the lab to be trained to recognize your cancer. While your cells are being prepared, you'll receive two chemotherapy medications to prepare your body. On day 0, you'll receive the trained cells back through an infusion and begin receiving high-dose medication to boost their activity. You'll stay in the hospital during this phase and be monitored closely for side effects. About 6 weeks after treatment, you'll have scans and tests to see if your tumors have shrunk.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States